These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10576464)

  • 1. Paroxetine versus citalopram treatment of pathological crying after brain injury.
    Müller U; Murai T; Bauer-Wittmund T; von Cramon DY
    Brain Inj; 1999 Oct; 13(10):805-11. PubMed ID: 10576464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors.
    Nahas Z; Arlinghaus KA; Kotrla KJ; Clearman RR; George MS
    J Neuropsychiatry Clin Neurosci; 1998; 10(4):453-5. PubMed ID: 9813792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression.
    Hieronymus F; Lisinski A; Nilsson S; Eriksson E
    Mol Psychiatry; 2018 Aug; 23(8):1731-1736. PubMed ID: 29155804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SSRIs and ejaculation.
    Robbins A
    J Clin Psychopharmacol; 2003 Feb; 23(1):108; author reply 108-9. PubMed ID: 12544388
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.
    Landén M; Högberg P; Thase ME
    J Clin Psychiatry; 2005 Jan; 66(1):100-6. PubMed ID: 15669895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    Miner CM; Brown EB; Gonzales JS; Munir R
    J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
    Mundo E; Bianchi L; Bellodi L
    J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
    Mullins CD; Shaya FT; Meng F; Wang J; Harrison D
    Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Citalopram treatment of paroxetine-intolerant depressed patients.
    Thase ME; Ferguson JM; Lydiard RB; Wilcox CS
    Depress Anxiety; 2002; 16(3):128-33. PubMed ID: 12415538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirtazapine versus selective serotonin reuptake inhibitors.
    Thompson C
    J Clin Psychiatry; 1999; 60 Suppl 17():18-22; discussion 46-8. PubMed ID: 10446737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases].
    Richard MA; Fiszenson F; Jreissati M; Jean Pastor MJ; Grob JJ
    Ann Dermatol Venereol; 2001; 128(6-7):759-61. PubMed ID: 11460042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment of post-stroke pathological laughing and crying.
    Giacobbe P; Flint A
    J Psychiatry Neurosci; 2007 Sep; 32(5):384. PubMed ID: 17823653
    [No Abstract]   [Full Text] [Related]  

  • 15. Escitalopram in disorder of laughter and crying with predominant laughter incontinence.
    Mohapatra D; Mishra BR; Maiti R; Das S
    J Basic Clin Physiol Pharmacol; 2017 Jan; 28(1):89-90. PubMed ID: 27987363
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram.
    Jacobsen PL; Nomikos GG; Zhong W; Cutler AJ; Affinito J; Clayton A
    CNS Spectr; 2020 Feb; 25(1):50-63. PubMed ID: 31010445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.
    Meyer JH; Wilson AA; Ginovart N; Goulding V; Hussey D; Hood K; Houle S
    Am J Psychiatry; 2001 Nov; 158(11):1843-9. PubMed ID: 11691690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.
    Koponen H; Lepola U; Leinonen E; Jokinen R; Penttinen J; Turtonen J
    Acta Psychiatr Scand; 1997 Nov; 96(5):343-6. PubMed ID: 9395151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
    Brent DA
    Depress Anxiety; 2009; 26(10):871-4. PubMed ID: 19798756
    [No Abstract]   [Full Text] [Related]  

  • 20. Tamoxifen-SSRIs interaction: clinical manifestations of inhibition and lack of inhibition of CYP2D6.
    Appiani F; Carroll BT; Muñoz C; Trecco J
    Ann Clin Psychiatry; 2011 May; 23(2):152-3. PubMed ID: 21547277
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.